cyrilzakka/clinical-trials huggingface dataset:
The Study of Apelin-APJ System on Pulmonary Hypertension Patients and Healthy Subjects

The purpose of this study is to

* Determine blood peptide levels and investigate any tissue gradients of apelin in patients with idiopathic pulmonary arterial hypertension and healthy volunteers.
* Evaluate the effect of exogenous apelin infusion on exercise performance in healthy volunteers and patients with idiopathic pulmonary arterial hypertension.

Idiopathic pulmonary arterial hypertension remains an enigma for physician in both diagnosis and treatment. Existing biomarkers, tissue characteristics and definite treatment are restricted. There are many evidences suggested that Apelin-APJ system associated with Idiopathic Pulmonary Arterial Hypertension (IPAH). A comprehensive characterise circulating peptide levels and investigate any tissue gradients of apelin in patients with idiopathic pulmonary arterial hypertension and healthy volunteers might provide important information about pathophysiologic process and diagnostic marker. In addition, first time human study to assessment the effect of exogenous apelin infusion on exercise performance in healthy volunteers and patients with idiopathic pulmonary arterial hypertension is essential to confirm whether the relevance between animal models and clinical subjects.

Eligibility Criteria:
Inclusion Criteria for Control group:

* Structurally normal heart by 2D Echocardiography
* Pulmonary artery pressure \< 25mmHg
* Tricuspid velocity \< 2.5ms-1

Inclusion Criteria for Treatment group:

* Clinical diagnosis of Pulmonary arterial hypertension that is idiopathic, associated with anorexigens associated with connective tissue disease or familial
* Able to give informed consent
* Mean pulmonary artery pressure \> 25mmHg, pulmonary capillary wedge pressure \< 15mmHg, with normal or reduced cardiac output.

Exclusion Criteria for ALL group:

* Bleeding diathesis (PT \> 14 sec to aPTT \> 40 sec)
* Pregnancy, or women of child bearing potential not on adequate contraception
* Renal or hepatic failure
* Severe valvular heart disease
* Left ventricular dysfunction (LVEF \< 40)
* Chronic lung disease
* Malignant arrhythmias
* Chronic thromboembolic disease
A Study of Intravenous Acetaminophen for Small Bowel Obstruction

The purpose of this study is to compare IV Acetaminophen for pain control to the usual care with opioids in patients admitted for small bowel obstruction.

The primary aim of this study is to assess the feasibility of conducting a randomized trial involving intravenous acetaminophen for pain control compared to usual care with opioids in patients admitted for small bowel obstruction and to summarize pain scores up to 72 hours after treatment. Patients presented and diagnosed with small bowel obstruction (SBO) will be screened for eligibility and will be offered participation in this study. Patients admitted for SBO for medical management with pain on admission will be eligible to participate in study. This will include patients with malignant and nonmalignant SBO. Participants will be randomly assigned into one of two groups, either the Treatment Group which receive IV acetaminophen or the Usual Care Group which will receive intravenous morphine or hydromorphone as needed for pain control. A Nasogastric (NG) tube will be placed when it is indicated, if patient is having significant nausea or vomiting. Pain scores will be followed as usual pain management assessment and reported in the medical record. Once SBO is resolved (usually 3 days after admission), active study participation will end. Participants may be followed via their medical record up to 30 days after discharge.

Eligibility Criteria:
Inclusion Criteria:

* Small bowel obstruction diagnosed by radiographic study; and
* Abdominal pain on admission.
* Nothing per mouth diet.
* The ability to give appropriate consent or have an appropriate representative available to do so.

Exclusion Criteria:

* Known liver failure or cirrhosis.
* Acetaminophen toxicity on admission.
* Known acetaminophen allergy.
* Alcohol intoxication on admission.
* History of substance abuse.
* Creatinine clearance \< 30 (or Creatinine level \> 2).
* Liver transplant recipients.
* Ileus on admission.
* Admitted for surgical intervention for SBO.
* Admitted for venting Gastric tube placement.
* On chronic opioid therapy (defined as use of opioid on daily or near daily basis within previous 45 days (both long acting and short acting).
* Presentation without abdominal pain on admission.
* Already hospitalized for other reasons and develop SBO while at the hospital.
* Pregnant women.
* Unable to provide informed consent.
The Evaluation of Single Acupoint Therapy to Acute Low Back Pain

Low back pain is the leading course of disability , affecting patients' health and work.

Recently, studies have reveal the fact that patients get insufficient physical activity and easily let acute stage turn to chronic type.

Although acupuncture for low back pain is worldwide popular, the mechanism of single acupoint for low back pain is still unclear.

Therefore, the aim of this study is the investigators choose the most frequent used acupoint and modified single acupoint method to assess the efficacy of single acupoint to acute low back pain.

Low back pain is the leading course of disability , affecting patients' health and work. According to the study in 2013, 8.9 percent people of the world experienced over three months low back pain.

Recently, studies have reveal the fact that patients get insufficient physical activity and easily let acute stage turn to chronic type.

Although acupuncture for low back pain is worldwide popular, the mechanism of single acupoint for low back pian is still unclear.

Therefore, the investigators choose the most frequent used acupoint and modified single acupoint method to assess the efficacy of single acupoint to acute low back pain.

The investigators would like to compare the efficacy of the modified Bladder 40 (BL40) acupuncture to single acupoint through statistical analysis.

The investigators expect that all group will alleviate low back pain. However, treatment group will have statistical difference compared with control groups.

The aim of this study is the investigators choose the most frequent used acupoint and modified single acupoint method to assess the efficacy of single acupoint to acute low back pain.

Eligibility Criteria:
Inclusion Criteria:

* low back pain,duration \< 1 month
* accept subject consent

Exclusion Criteria:

* without X ray or MRI image
* severe trauma , fracture or spondylosis found from image ,progression neurological symptoms suspected from central nerve system, rheumatic disease, fever or infection is suspected ,weight or cancer history , pregnancy and psychiatric disorder or not able to communication .
Metformin as Adjuvant to Insulin Therapy in Insulin-resistant Diabetes Mellitus With Pregnancy

Adding metformin to insulin therapy in pregnant women with diabetes mellitus who show insulin resistance may be equivalently effective to further raising the insulin dose


Eligibility Criteria:
Inclusion Criteria:

* pregnant women with insulin-resistant diabetes mellitus

Exclusion Criteria:

* type-1 diabetes mellitus
* secondary diabetes mellitus
Mail Order Mifepristone Study

This study aims to evaluate the feasibility, acceptability, and effectiveness of dispensing mifepristone via a mail-order pharmacy. The investigators will recruit patients at up to 10 primary care and internal medicines sites not currently providing abortion services around the country, as well as abortion clinic sites. Patients will go through routine in clinic visits to determine eligibility and then will receive the medications in the mail at their preferred address. The investigators will survey patients 3 and 14 days after the initial clinic visit and interview providers at the end of the study.

This is a prospective cohort study of patients obtaining medication abortion via mifepristone dispensed from an online mail order pharmacy. After an initial pilot test with 25 patients, the investigators will identify 10 clinics to participate in the study. The study team will train primary care providers not currently providing abortion to provide medication abortion with the medications dispensed via mail order pharmacy. The investigators aim to recruit up to 650 patients for this study across all the sites. Patients will come in for an initial consult visit at the study site and then receive their medications at a preferred address within 3 days of the initial visit. Study participants will fill out surveys about their experience and feedback about the acceptability of the process; this will occur at 3 and 14 days after the initial recruitment visit. The investigators will also collect clinic data from patients and clinic sites to track clinical outcomes. And the investigators will interview providers at the end of the study to better understand their experiences prescribing mifepristone via mail-order.

Eligibility Criteria:
Inclusion Criteria:

* Women seeking medication abortion through 63 days gestation
* Eligible for MifeprexⓇ at a study site
* English or Spanish speaking
* Willing and able to participate in the study, including willing and able to receive medications at home or other preferred address within 3 days of initial medication abortion visit

Exclusion Criteria:

* Not pregnant
* Not seeking medication abortion
* under the age of 15
* Over 63 days gestation
* Contraindicated for medication abortion
The Effect of a Gamified Neuropathy Management Application on Cancer Behavior in Cancer Patients Undergoing Chemotherapy

This study will be conducted to determine the effect of a gamified neuropathy management application on cancer behavior in cancer patients undergoing chemotherapy.

Cancer patients may experience treatment-related issues throughout their treatment process. Chemotherapy-induced peripheral neuropathy is one of the symptoms that negatively affects patients' overall health status. Peripheral neuropathy can occur during or after chemotherapy, leading to sensory, motor, and autonomic nerve damage. It is particularly common among cancer patients receiving taxane- and platinum-based chemotherapy.

Effective management of neuropathy is a crucial aspect of nursing care. Here are some key points regarding this issue: pharmacological and non-pharmacological methods, lifestyle control, and nursing interventions are employed. The management of peripheral neuropathy can have a significant impact on the overall health and well-being of cancer patients undergoing chemotherapy. Nurses play a vital role in this process by providing support that enhances patients' quality of life and improves treatment outcomes.

Gamification applications, which have recently started to be used in patient education, represent a contemporary approach. However, no studies have been found utilizing gamification specifically in patient education for cancer. For this reason, this study aims to contribute to patients' neuropathy management using a gamification application.

Eligibility Criteria:
Inclusion Criteria:

* Undergoing chemotherapy treatment and have completed their first cycle.
* Literate (able to read and write).
* Able to use a smartphone.
* Aged between 18 and 65 years.
* Willing to participate in the study voluntarily.

Exclusion Criteria:

* Participants who do not use the application during the study period
* Participants who fail to complete the data collection forms
Apparent Diffusion Coefficient as a Prognostic Biomarker in Cervical Cancer

This study aims to develop the technique of Diffusion-Weighted Magnetic Resonance Imaging(DW-MRI)for the assessment of stage 1 cervical cancers. An endovaginal receiver coil has been designed and developed at the Institute of Cancer Research and Royal Marsden NHS Foundation Trust for use at high field strengths(3T). This will be used to evaluate if DW-MRI at 3T can be used to differentiate different histological characteristics within whole tumours and so determine if the technique could be of prognostic value.

The study hypothesis is that this technique will be able to differentiate tumours with histological features known to be associated with poor prognosis (tumour type, grade and lymphovascular space invasion).


Eligibility Criteria:
Inclusion Criteria:

* All patients with presumed early stage cervical cancer being considered for curative surgery

Exclusion Criteria:

* Ferromagnetic metal implants
* claustrophobia (MRI incompatibility)
Safety and Efficacy of FT218 in Idiopathic Hypersomnia (REVITALYZ)

This is a double-blind, placebo-controlled, randomized withdrawal, multicenter study of the efficacy and safety of FT218. FT218 drug product is a once-nightly formulation of sodium oxybate for extended-release oral suspension. The study will enroll subjects who are diagnosed with idiopathic hypersomnia. Subjects will be eligible to enroll regardless of current treatment with oxybate therapy or stimulants/alerting agents at study entry. The estimated total duration of study for each subject is approximately 18 weeks, including the Screening period.


Eligibility Criteria:
Inclusion Criteria:

* Primary diagnosis of idiopathic hypersomnia
* Total ESS score at Screening \> 11 if not on prior oxybate
* Average nightly total sleep time of \> 7 hours
* May use stimulants/alerting agents but dose and regimen must have been stable for 2 months prior to Screening, and remain stable until the double-blind, randomized withdrawal visit
* Females of childbearing potential must use highly effective contraception for 2 months prior to Baseline, throughout the study, and for 30 days after the last dose of study drug
* Males with female partners of childbearing potential must use condoms throughout the study and for 30 days after the last dose of study drug
* Willing and able to provide informed consent and comply with the requirements of the study

Exclusion Criteria:

* Pregnant, nursing or lactating females
* Hypersomnia due to another medical, behavioral, sleep, or psychiatric condition
* Untreated or incompletely treated sleep apnea in patients with an apnea-hypopnea index (AHI) ≥ 15 by American Academy of Sleep Medicine (AASM) 1A criteria
* Clinically significant parasomnias
* History or presence of seizures, head trauma, succinic semialdehyde dehydrogenase deficiency, uncontrolled hypothyroidism, and/or significant hepatic impairment
* History or presence of bipolar and related disorders, schizophrenia, schizophrenia spectrum disorders, or other psychotic disorders
* Ongoing or past (within 1 year) major depressive episode
* At risk for suicide or history of suicide attempt
* If not on oxybate at Screening, treatment or planned treatment with any central nervous system (CNS) sedating agents during study
* Current or past substance use disorder (including alcohol or cannabinoids)
* Excessive caffeine consumption (\> 600 mg/day)
* Prior treatment with either FT218 or LUMRYZ
IRIS Registry: Intelligent Research in Sight Registry

The IRIS™ Registry (Intelligent Research in Sight) is the nation's first comprehensive eye disease clinical registry. The American Academy of Ophthalmology is developing it as part of the profession's shared goal of continual improvement in the delivery of eye care.The IRIS Registry will be a centralized system for ophthalmology practices to promote practice innovations and achieve clinical excellence.

The IRIS Registry is primarily a clinical self-improvement tool. It will allow ophthalmologists to compare their patient outcomes, professional performance and care processes against other ophthalmologists across the country. The IRIS Registry will be able to measure the continuum of care from initial patient contact, through intervention and follow up.

Improve Patient Care - Monitor patient interactions, track interventions, identify and address gaps in quality of care, and measure quality outcomes.

Manage Patient Populations - Proactively manage clinical conditions for entire patient populations by running reports on specific care criteria.

Benchmark Your Practice - Identify practice strengths and weaknesses using the IRIS Registry's ophthalmology-specific clinical data from other practices to compare to the performance and outcomes data of your practice.

Run quality reports on demand - Providing clinician- and practice-level results, plus national results and patient-level detail for all IRIS Registry measures.

Enhance Quality and Practice Efficiency - Use the IRIS Registry data to analyze practice processes and procedures and as a source for fact-based decision-making. Because the IRIS Registry will capture data over time at the individual and practice level, it will help practices efficiently manage patient care and optimize practice resources.

Join a Community of Quality - Become a member of a like-minded community of quality-driven professionals striving to continuously improve patient care. Interact with your peers to create opportunities for sharing quality improvement strategies and broaden your professional network.

Eligibility Criteria:
Inclusion Criteria:

* Patients who meet the denominator requirements for each measure.

Exclusion Criteria:

* None
Efficacy and Safety Study of Oral CEM-101 Compared to Oral Levofloxacin in Treatment of Patients With Community-Acquired Bacterial Pneumonia

Study to evaluate the safety and efficacy of oral CEM-101 compared to oral Levofloxacin in the treatment of adults with moderate to moderately severe community-acquired bacterial pneumonia.

Community-acquired bacterial pneumonia is an acute infection of the pulmonary parenchyma with symptoms such as fever or hypothermia, chills, rigors, chest pain, and/or dyspnea. The widespread emergence of antibiotic resistant pathogens, including the macrolide-resistant Streptococcus pneumoniae, has resulted in a need for new and effective antibiotics that have activity again CABP pathogens. CEM-101 is the first fluoroketolide with excellent in vitro and in vivo activity against resistant S. pneumoniae and other key typical and atypical bacterial respiratory pathogens.

Eligibility Criteria:
Inclusion Criteria:

1. Diagnosis of community acquired bacterial pneumonia (e.g. cough with purulent sputum or change in character of sputum consistent with bacterial infection, dyspnea or tachypnea, chest pain due to pneumonia, fever, presence of rales and/or signs of consolidation).
2. No prior systemic antibacterial therapy, unless failed other therapy.
3. Chest Xray shows new lobar or multilobar infiltrate(s) consistent with acute bacterial pneumonia.
4. PORT Risk Class II, III, or IV \<=105
5. Ability to take oral medication.

Exclusion Criteria:

1. Severe chronic obstructive pulmonary disease FEV1 \<30%.
2. Hospitalization within 90 days or residence in a long-term-care facility within 30 days prior to the onset of symptoms
3. Chemotherapy or radiation therapy within the previous 3 months.
4. Significant hepatic, hematological, renal abnormalities.
5. Any concomitant condition that, in the opinion of the Investigator, would preclude an evaluation of a response or make it unlikely that the contemplated course of therapy and follow-up could be completed (e.g. life expectancy \<30 days).
Promoting Healing of Injured Nerves With Electrical Stimulation Therapy

This study is evaluating a new therapeutic use of electrical stimulation to promote nerve healing and improve functional recovery following surgical intervention for peripheral nerve injury in arm. Participants will be randomized into one of two groups, treatment or control, with all participants receiving standard of care treatment for the nerve injury. The treatment group will also receive a single dose of the therapeutic stimulation during the surgical intervention for their nerve injury.

Preliminary research has shown that delivering a brief period of electrical stimulation following nerve repair promotes nerve healing and functional recovery. This pilot study is investigating the use of a single dose of therapeutic electrical stimulation to promote nerve healing. The therapy is delivered as part of the surgical intervention to address peripheral nerve injury in the arm.

Eligibility Criteria:
Inclusion Criteria:

* Upper extremity mixed or motor nerve injury from the brachial plexus to the wrist crease.
* Candidate for surgical intervention.
* Indicated for surgical repair by nerve transfer, primary repair, or nerve grafting.
* Are age 18-80 years.
* Signed and dated informed consent form.

Exclusion Criteria:

* Severe comorbid condition, such as arrhythmia or congestive heart failure, preventing surgery.
* Primary repair requiring graft \>6cm.
* Nerve reconstruction occurring \>12 months post injury.
* Age less than 18 or greater than 80 years.
* All contraindications to included/required surgical procedure, including but not limited to language barriers, mental status barriers, inability to consent, and pregnancy/lactation.
Gabapentin to Improve Patient Tolerance in Endoscopic Retrograde Cholangiopancreatography (ERCP)

The standard approach to sedation in endoscopic retrograde cholangiopancreatography (ERCP) involves the use of benzodiazepines and opiates to achieve a moderate depth of sedation. There is data to suggest supplementing this regimen with gabapentin may lead to reduced pain, higher patient satisfaction and lower opiate requirements. The investigators are conducting a clinical trial to study this hypothesis.


Eligibility Criteria:
Inclusion Criteria:

* Male or female patients \>18 years of age referred to IUMC for first-time ERCP procedure.

Exclusion Criteria:

1. Pregnant women
2. age \<18 years
3. Incarcerated individuals
4. Patients currently taking or having taken gabapentin or pregabalin within the last 3 months
5. Patients unable to give informed consent
6. Patients not able to fill out visual analog scales for pain, nausea and anxiety or unable to fill out survey regarding procedural satisfaction.
7. High risk patients for anesthesia: home oxygen, class III or IV heart failure, sleep apnea (on CPAP/BiPAP at home), or ASA class \> 3.
8. Patients undergoing general anesthesia for their ERCP procedure
9. Patients receiving propofol sedation for their ERCP procedure
Quality of Recovery of Remimazolam Versus Sevoflurane in Transurethral Bladder Resection.

This study was designated to investigate the quality of recovery after transurethral bladder resection. Because, patients undergoing transurethral bladder resection are mostly old age, and because of catheter-related bladder discomfort are common after transurethral bladder resection, study on the quality of recovery after transurethral bladder resection seems to be meaningful. In general, sevoflurane is commonly used as an anesthetic agent for general anesthesia of transurethral bladder resection. The purpose of this study is to investigate whether remimazolam is not inferior to sevoflurnane in terms of quality of recovery after transurethral bladder resection.


Eligibility Criteria:
Inclusion Criteria:

* adult patients aged from 19 years
* Americaln Society of Anesthesiologist's class I, II, and III
* scheduled to undergo elective transurethral bladder resection under general anesthesia

Exclusion Criteria:

* refuse to participate in the study
* cannot read, or sign the consent form (e.g., iliterate, foreigner, eye disease)
* history of allergy to benzodiazepines
* decreased liver, kidney, or heart function
* pregnant women or breastfeeding patients
* history of drug or alcohol abuse
* obesity (body mass index \> 30kg/m2)